TransMedics Group, Inc. is a medical technology company specializing in organ transplant therapy for end-stage organ failure. The company develops the Organ Care System (OCS), a portable, multi-organ warm perfusion platform that preserves donor organs by replicating near-physiologic conditions outside the human body. Its product portfolio includes OCS Heart, OCS Lung, and OCS Liver, all of which have received FDA Pre-Market Approval for organs donated after brain death and circulatory death. TransMedics also operates the National OCS Program (NOP), an end-to-end service offering that provides outsourced organ procurement, perfusion management, and transplant logistics, including aviation and ground transportation. In August 2023, the company acquired Summit Aviation, Inc. and Northside Property Group, LLC to expand its air transport capabilities. The company serves transplant centers in the United States and has operations in Europe. Its business model relies on recurring revenue from single-use disposable sets and NOP services, with reimbursement through standard commercial transplant billing mechanisms, Medicare, and private payors.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage transmedics.com
Sector Healthcare IR page investors.transmedics.com
Tags
organ transplantation, organ perfusion, organ preservation, heart transplant, lung transplant, liver transplant, transplant logistics, organ procurement, medical technology, Organ Care System, OCS, OCS Heart, OCS Lung, OCS Liver, National OCS Program, NOP, Summit Aviation Inc., Northside Property Group LLC
Press page —

Metrics

Valuation  
Market cap $ 3.28B
Market cap (USD) $ 3.28B
P/E 25.81
PEG —
P/BV 5.96
P/S 4.51
P/OCF 29.19
P/FCF 73.39
Dividend yield —
Turnover / mcap —
Returns  
ROE 54.2%
ROI 19.3%
ROIC 11.0%
Profit margin 31.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 108.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 605.494M 441.54M 241.623M 93.459M 31.385M 28.356M 25.844M 14.657M
Net profit 190.291M 35.464M -25.028M -36.231M -44.215M -28.748M -33.547M -23.756M
Free cash flow 133.589M -80.941M -164.875M -57.724M -32.383M -30.72M -32.451M -26.402M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 121.65 62.35 78.93 61.72 19.16 19.9 19.01 —
Price performance 12m 0.95 -0.21 0.28 2.22 -0.04 0.05 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 3.44M 6.56M 6.86M 5.93M 27.6M 63.6M 97.7M 84.3M
↳ YoY growth +90.8% +4.7% -13.5% +365.3% +130.3% +53.7% -13.8%
↳ 5y CAGR +79.2% +71.6% +65.1%
Borrowings, current (USD) — — — — — — — — 10M
Borrowings, non-current (USD) — 33.7M 34.1M 34.7M 35.2M 58.7M — — —
Lease liabilities (USD) — — — — 8.6M 8.86M 9.74M 8.98M 6.89M
Cash and deposits (USD) 12.4M 20.2M 20.1M 24.6M 25.6M 201M 395M 337M 489M
Intangible assets (USD) — — — — — — 2.35M 2.15M 1.95M
Right-of-use assets (USD) — — — — 5.85M 5.13M 6.55M 6.48M 5.16M
Net debt (borrowings + leases - cash) (USD) — 13.4M 14.1M 10.1M 18.2M -134M — — -472M
Cash flow detail
Operating cash flow (USD) — -26M -32.3M -30.3M -28.9M -45.8M -13M 48.8M 193M
Purchases of property, plant and equipment (USD) — -418,000 -165,000 -455,000 -3.52M -11.9M -152M -130M -59.3M
Change in receivables (cash effect) (USD) — -2.51M -3.17M -218,000 840,000 -21.7M -33.8M -34.3M 14M
Change in inventories (cash effect) (USD) — -2.7M -4.12M -1.74M -4.89M -8.02M -28.1M -8.35M -7.72M
Change in payables (cash effect) (USD) — 164,000 3.44M -5.8M 5.09M -3.27M 6.96M -1.4M -19,000
Interest paid (cash effect) (USD) — -2.4M -3.88M -3.48M -3.33M -3.26M -8.09M -11.3M -10.7M
Income taxes paid (cash effect) (USD) — — — — — — — — -1.15M
Share-based compensation (USD) — 144,000 854,000 2.41M 6.88M 10.3M 19.8M 33.2M 36.9M
Operating cash flow before change in receivables (USD) — -23.5M -29.1M -30M -29.7M -24.1M 20.8M 83.1M 179M
Free cash flow (OCF - PPE - intangibles) (USD) — -26.4M -32.5M -30.7M -32.4M -57.7M -165M -80.9M 134M
Income detail
Research and development expense (USD) — 13.7M 19.9M 18.8M 22.3M 26.8M 36.1M 56M 69.1M
↳ 5y CAGR +21.4% +23.0% +29.7%
Total comprehensive income (USD) — -23.7M -33.4M -28.8M -44.3M -36.3M -25M 35.3M 191M
Comprehensive income to owners (USD) — -23.7M -33.4M -28.8M -44.3M -36.3M -25M 35.3M 191M
Provision for credit losses (USD) — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Reported Jun 12, 2019 Mar 17, 2020 Mar 17, 2020 Mar 11, 2021 Mar 1, 2022 Feb 27, 2023 Feb 27, 2024 Feb 27, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts

Andover, Mass. – November 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

•Total revenue of $203.0 million, up 41%, including organic revenue growth* of 35%

•Product revenue of $113.4 million, up 29%, and service revenue of $89.6 million, up 60%, including organic service revenue growth* of 43%

•Net income of $17.1 million or $0.46 per diluted share in the third quarter of 2026

•Adjusted net income* of $18.9 million or $0.51 per diluted share in the third quarter of 2026

•Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation

Recent Business Highlights

•Completed enrollment in Part A of the Next-Generation Organ Care System (OCS) ENHANCE Heart trial (September) and received U.

Oct 22, 2026 at 4:05 PM EDT

PDF Version

ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

TransMedics Logo. (PRNewsFoto/TransMedics, Inc.)

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 6054544. A live and archived webcast of the event will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.

**About TransMedics Group, Inc.**TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

**Investor Contact:**Brian Johnston Gilmartin Group [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-to-report-third-quarter-2026-financial-results-on-november-5-2026-302917373.html

SOURCE TransMedics Group, Inc.

Andover, Mass. – September 10, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Mr. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M to support the Company’s next phase of global growth. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Advisor, LATAM to lead TransMedics’ expansion into Latin America. Concurrent with today’s announcement, TransMedics is reiterating its full-year revenue guidance for 2026.

Mr. Araujo is a global finance executive with more than 20 years of public-company experience across the healthcare, industrial, and energy sectors. Most recently, he served as Chief Financial Officer of GE HealthCare’s Advanced Imaging Solutions segment, a $16 billion segment combining GE HealthCare’s Imaging and Advanced Visualization Solutions businesses with its global Integrated Supply Chain and Global Service organizations.

Prompts

TransMedics Group, Inc. (ticker TMDX), listed in United States.

ETFs Holding TransMedics Group, Inc.

ETF Weight in ETF Shares Market value As of
LFSC 2.91% 43,305 $ 3.675M Aug 31, 2026
ULTY 2.69% 148,100 $ 13.656M Nov 17, 2026
SPIT 2.35% 9,383 $ 796.335K Aug 31, 2026
CSMD 1.60% 95,152 $ 7.28M Jul 31, 2026
SSMG 0.92% 385 $ 29.456K Jul 31, 2026
FFSM 0.33% 64,809 $ 4.959M Jul 31, 2026
MKTN short -0.22% -3,538 $ -234.994K Jun 30, 2026
PSC 0.20% 71,124 $ 4.724M Jun 30, 2026
AVSC 0.17% 59,806 $ 5.515M Nov 16, 2026
ESSC 0.10% 492 $ 37.643K Jul 31, 2026
RESM 0.10% 57 $ 3,785.94 Jun 30, 2026
SMDX 0.09% 1,239 $ 114.248K Nov 17, 2026
IALT short -0.07% -57,469 $ -5.299M Nov 16, 2026
DFAS 0.07% 248,730 $ 22.883M Nov 12, 2026
DXUV 0.03% 19,694 $ 1.812M Nov 12, 2026
MSSM 0.02% 1,687 $ 143.176K Aug 31, 2026
AVUS 0.01% 14,182 $ 1.308M Nov 16, 2026
DFSU 0.01% 2,503 $ 230.276K Nov 12, 2026
DFAC 0.01% 74,320 $ 6.837M Nov 12, 2026
DCOR 0.01% 24,571 $ 2.261M Nov 12, 2026
DFAU 0.00% 6,877 $ 632.684K Nov 12, 2026
DFUS 0.00% 9,998 $ 919.816K Nov 12, 2026
DFUV 0.00% 350 $ 32.2K Nov 12, 2026
AVSU 0.00% 76 $ 7,007.96 Nov 16, 2026